Inovio Pharmaceuticals, Inc.

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 21/09/2026 +03			5-day change	1st Jan Change
1.240 ^USD	0.00%		-0.80%	-28.74%

09-11	Inovio Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-11-2026 07:00 AM
09-10	Inovio Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 03:20 PM

Top Premarket Decliners

Published on 07/30/2026 at 03:44 pm +03

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Inovio Pharmaceuticals, Inc.

09-11	Inovio Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-11-2026 07:00 AM
09-10	Inovio Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 03:20 PM
08-13	Jefferies Upgrades Inovio Pharmaceuticals to Buy From Hold, Adjusts PT to $3 From $1.80	MT
08-13	Inovio Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	Top Premarket Decliners	MT
07-03	Inovio Pharmaceuticals Files $300 Million Mixed Shelf Offering	MT
07-02	Certain Restricted Stock Units of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-JUL-2026.	CI
07-02	Certain Stock Options of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-JUL-2026.	CI
07-02	Certain Common Stock of Inovio Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 2-JUL-2026.	CI
06-29	Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell 3000E Growth Benchmark	CI
06-29	Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Microcap Growth Benchmark Index	CI
06-04	Inovio Pharmaceuticals, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 08:45 AM
05-22	Inovio Says China Partner Reported VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint in Cervical Dysplasia Patients	MT
05-14	Inovio reports first quarter 2026 financial results and recent business highlights	RE

Chart Inovio Pharmaceuticals, Inc.

Duration

Period

INO: Dynamic Chart

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the bodyâ€™s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Employees

112

Sector

Biotechnology & Medical Research

More about the company